Relative Effectiveness and Safety of the GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists, Semaglutide and Liraglutide in the Treatment of Obese Type 2 Diabetics: A Prospective Observational Cohort Study in Poland
Karolina Hoffmann,1 Michał Michalak,2 Anna Paczkowska3 1Department and Clinic of Internal Diseases and Metabolic Disorders, Poznan University of Medical Sciences, Poznań, Poland; 2Department of Computer Science and Statistics, Poznan University of Medical Sciences, Pozn...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-08-01
|
| Series: | Diabetes, Metabolic Syndrome and Obesity |
| Subjects: | |
| Online Access: | https://www.dovepress.com/relative-effectiveness-and-safety-of-the-glp-1-glucagon-like-peptide-1-peer-reviewed-fulltext-article-DMSO |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850033248838615040 |
|---|---|
| author | Hoffmann K Michalak M Paczkowska A |
| author_facet | Hoffmann K Michalak M Paczkowska A |
| author_sort | Hoffmann K |
| collection | DOAJ |
| description | Karolina Hoffmann,1 Micha&lstrok; Michalak,2 Anna Paczkowska3 1Department and Clinic of Internal Diseases and Metabolic Disorders, Poznan University of Medical Sciences, Pozna&nacute;, Poland; 2Department of Computer Science and Statistics, Poznan University of Medical Sciences, Pozna&nacute;, Poland; 3Department of Pharmacoeconomics and Social Pharmacy, Poznan University of Medical Sciences, Pozna&nacute;, PolandCorrespondence: Karolina Hoffmann, Department and Clinic of Internal Diseases and Metabolic Disorders, Poznan University of Medical Sciences, Przybyszewskiego 49 Street, 60-355, Pozna&nacute;, Poland, Tel +4861 8549 377, Fax +4861 8478 529, Email karolinahoffmann@ump.edu.plPurpose: To compare the efficacy and safety of semaglutide and liraglutide over one year in obese Polish patients with type 2 diabetes.Patients and Methods: In this prospective, observational cohort study conducted in Poland in 2024, 460 patients aged 18– 80 were enrolled: 333 received semaglutide (Group 1), and 133 received liraglutide (Group 2).Results: After 12 months, HbA1c levels significantly decreased in both groups: Group 1: from 6.09 ± 1.14% to 5.42 ± 0.82% (mean decrease: 0.67 ± 0.37%, p< 0.0001). Group 2: from 5.78 ± 0.75% to 5.17 ± 0.54% (mean decrease: 0.61 ± 0.28%, p< 0.001). BMI decreased by 5.36 ± 3.45 kg/m² in Group 1 and 4.41 ± 4.63 kg/m² in Group 2 (p< 0.0001), with greater reduction in Group 1 (p=0.017). Gastrointestinal adverse effects were most common, including nausea, vomiting, constipation, gastritis, and diarrhea, with higher incidence in Group 1. HbA1c reduction correlated with baseline HbA1c, age, and gender; BMI reduction correlated with baseline HbA1c and BMI.Conclusion: Semaglutide was more effective than liraglutide in reducing HbA1c and BMI. Gastrointestinal symptoms were the most frequent side effects in both groups.Keywords: GLP-1 receptor agonist, semaglutide, liraglutide, obesity, type 2 diabetes |
| format | Article |
| id | doaj-art-3d49f74b61e14d62b136227b58f9502c |
| institution | DOAJ |
| issn | 1178-7007 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Diabetes, Metabolic Syndrome and Obesity |
| spelling | doaj-art-3d49f74b61e14d62b136227b58f9502c2025-08-20T02:58:18ZengDove Medical PressDiabetes, Metabolic Syndrome and Obesity1178-70072025-08-01Volume 18Issue 127232738105572Relative Effectiveness and Safety of the GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists, Semaglutide and Liraglutide in the Treatment of Obese Type 2 Diabetics: A Prospective Observational Cohort Study in PolandHoffmann K0Michalak M1Paczkowska A2Department and Clinic of Internal Diseases and Metabolic DisordersDepartment of Computer Science and StatisticsDepartment of Pharmacoeconomics and Social PharmacyKarolina Hoffmann,1 Micha&lstrok; Michalak,2 Anna Paczkowska3 1Department and Clinic of Internal Diseases and Metabolic Disorders, Poznan University of Medical Sciences, Pozna&nacute;, Poland; 2Department of Computer Science and Statistics, Poznan University of Medical Sciences, Pozna&nacute;, Poland; 3Department of Pharmacoeconomics and Social Pharmacy, Poznan University of Medical Sciences, Pozna&nacute;, PolandCorrespondence: Karolina Hoffmann, Department and Clinic of Internal Diseases and Metabolic Disorders, Poznan University of Medical Sciences, Przybyszewskiego 49 Street, 60-355, Pozna&nacute;, Poland, Tel +4861 8549 377, Fax +4861 8478 529, Email karolinahoffmann@ump.edu.plPurpose: To compare the efficacy and safety of semaglutide and liraglutide over one year in obese Polish patients with type 2 diabetes.Patients and Methods: In this prospective, observational cohort study conducted in Poland in 2024, 460 patients aged 18– 80 were enrolled: 333 received semaglutide (Group 1), and 133 received liraglutide (Group 2).Results: After 12 months, HbA1c levels significantly decreased in both groups: Group 1: from 6.09 ± 1.14% to 5.42 ± 0.82% (mean decrease: 0.67 ± 0.37%, p< 0.0001). Group 2: from 5.78 ± 0.75% to 5.17 ± 0.54% (mean decrease: 0.61 ± 0.28%, p< 0.001). BMI decreased by 5.36 ± 3.45 kg/m² in Group 1 and 4.41 ± 4.63 kg/m² in Group 2 (p< 0.0001), with greater reduction in Group 1 (p=0.017). Gastrointestinal adverse effects were most common, including nausea, vomiting, constipation, gastritis, and diarrhea, with higher incidence in Group 1. HbA1c reduction correlated with baseline HbA1c, age, and gender; BMI reduction correlated with baseline HbA1c and BMI.Conclusion: Semaglutide was more effective than liraglutide in reducing HbA1c and BMI. Gastrointestinal symptoms were the most frequent side effects in both groups.Keywords: GLP-1 receptor agonist, semaglutide, liraglutide, obesity, type 2 diabeteshttps://www.dovepress.com/relative-effectiveness-and-safety-of-the-glp-1-glucagon-like-peptide-1-peer-reviewed-fulltext-article-DMSOGLP-1 receptor agonistsemaglutideliraglutideobesitytype 2 diabetes |
| spellingShingle | Hoffmann K Michalak M Paczkowska A Relative Effectiveness and Safety of the GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists, Semaglutide and Liraglutide in the Treatment of Obese Type 2 Diabetics: A Prospective Observational Cohort Study in Poland Diabetes, Metabolic Syndrome and Obesity GLP-1 receptor agonist semaglutide liraglutide obesity type 2 diabetes |
| title | Relative Effectiveness and Safety of the GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists, Semaglutide and Liraglutide in the Treatment of Obese Type 2 Diabetics: A Prospective Observational Cohort Study in Poland |
| title_full | Relative Effectiveness and Safety of the GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists, Semaglutide and Liraglutide in the Treatment of Obese Type 2 Diabetics: A Prospective Observational Cohort Study in Poland |
| title_fullStr | Relative Effectiveness and Safety of the GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists, Semaglutide and Liraglutide in the Treatment of Obese Type 2 Diabetics: A Prospective Observational Cohort Study in Poland |
| title_full_unstemmed | Relative Effectiveness and Safety of the GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists, Semaglutide and Liraglutide in the Treatment of Obese Type 2 Diabetics: A Prospective Observational Cohort Study in Poland |
| title_short | Relative Effectiveness and Safety of the GLP-1 (Glucagon-Like Peptide 1) Receptor Agonists, Semaglutide and Liraglutide in the Treatment of Obese Type 2 Diabetics: A Prospective Observational Cohort Study in Poland |
| title_sort | relative effectiveness and safety of the glp 1 glucagon like peptide 1 receptor agonists semaglutide and liraglutide in the treatment of obese type 2 diabetics a prospective observational cohort study in poland |
| topic | GLP-1 receptor agonist semaglutide liraglutide obesity type 2 diabetes |
| url | https://www.dovepress.com/relative-effectiveness-and-safety-of-the-glp-1-glucagon-like-peptide-1-peer-reviewed-fulltext-article-DMSO |
| work_keys_str_mv | AT hoffmannk relativeeffectivenessandsafetyoftheglp1glucagonlikepeptide1receptoragonistssemaglutideandliraglutideinthetreatmentofobesetype2diabeticsaprospectiveobservationalcohortstudyinpoland AT michalakm relativeeffectivenessandsafetyoftheglp1glucagonlikepeptide1receptoragonistssemaglutideandliraglutideinthetreatmentofobesetype2diabeticsaprospectiveobservationalcohortstudyinpoland AT paczkowskaa relativeeffectivenessandsafetyoftheglp1glucagonlikepeptide1receptoragonistssemaglutideandliraglutideinthetreatmentofobesetype2diabeticsaprospectiveobservationalcohortstudyinpoland |